Format

Send to

Choose Destination
Nat Rev Cancer. 2008 Dec;8(12):942-56. doi: 10.1038/nrc2524.

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

Author information

1
Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin, Berlin, Germany.

Abstract

Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove successful in the clinic. After numerous patients with cancer or age-related macular degeneration have been treated with these drugs, they have now become part of the standard range of therapeutic tools. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles, such as improving efficacy, avoiding escape and resistance, and minimizing toxicity. Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment.

PMID:
19029957
DOI:
10.1038/nrc2524
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center